en · de · es
nad-notes.peptides6155.com › Wiki › Background And Mechanism Of Sr9009 — Background and Details

Background And Mechanism Of Sr9009 — Background and Details

By Editorial Desk · published 2026-01-25 · last reviewed 2026-02-25 · Wiki

A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Related pages on this site

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Reference notes

Israel has used Palestinian children as human shields in Gaza in violation of Geneva conventions. Human rights groups have said that "even if Hamas were using human shields", Israel must still abide by international law, especially the principle of proportionality. In May 2023, before the beginning of the Gaza war, Defence for Children International – Palestine (DCIP) had already documented that five children had been used as human shields by the Israeli army since the beginning of that year, with two of the victims being 2-year-old twins. According to a 2024 Haaretz investigation based on many Israeli soldiers' testimony, Palestinian teenagers, adults, and occasionally elderly men are regularly used as human shields to explore the tunnel network in the Gaza Strip. These shawashim are dressed up, apart from sandshoes, to look like Israeli soldiers, handcuffed, blindfolded and, with a video camera attached to their bodies, sent into houses where Hamas combatants are suspected to hide, or into tunnels that might be booby-trapped. The practice is said to be widely known to IDF field commanders. Palestinians were used when neither sniffer dogs nor drones were available. An October 2024 investigation by CNN found that while the scale and scope of the practice was unknown, testimony from civilians and an Israeli soldier showed Israel's use of Palestinians as human shields was widespread across the Gaza Strip.

== Clinical Signs == Early in the disease process, DSLD may cause only mild or sporadic lameness, making early detection challenging. As the disease advances, distinct signs like heat, swelling, and pain in the suspensory ligaments emerge. An altered gait or a flat-footed stance due to a sinking fetlock joint are also indicative of the disease, often leading to significant fetlock joint arthritis. DSLD was originally described in Peruvian Pasos, and this breed remains the most commonly affected. It has also been found in many other breeds, including Arabians, Thoroughbreds, American Quarter Horses, Morgans, Paso Finos, American Saddlebreds, several breeds of warmblood, Appaloosas, Friesians, Missouri Fox Trotters, Tennessee Walkers, American Paint Horses, National Show Horses, and Mustangs, as well as crossbreds and mules.

Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.

Uranium, like all elements with an atomic number greater than 82, has no stable isotopes. All isotopes of uranium are radioactive because the strong nuclear force does not prevail over electromagnetic repulsion in nuclides containing more than 82 protons. Nevertheless, the two most stable isotopes, 238U and 235U, have half-lives long enough to occur in nature as primordial radionuclides, with measurable quantities having survived since the formation of the Earth. These two nuclides, along with thorium-232, are the only confirmed primordial nuclides heavier than nearly-stable bismuth-209. Natural uranium consists of three major isotopes: uranium-238 (99.28% natural abundance), uranium-235 (0.71%), and uranium-234 (0.0054%). There are also five other trace isotopes: uranium-240, a decay product of plutonium-244; uranium-239, which is formed when 238U undergoes spontaneous fission, releasing neutrons that are captured by another 238U atom; uranium-237, which is formed when 238U captures a neutron but emits two more, which then decays to neptunium-237; uranium-236, which occurs in trace quantities due to neutron capture on 235U and as a decay product of plutonium-244; and finally, uranium-233, which is formed in the decay chain of neptunium-237. Additionally, uranium-232 would be produced by the double beta decay of natural thorium-232, though this energetically possible process has never been observed. Uranium-238 is the most stable isotope of uranium, with a half-life of about 4.463×109 years, roughly the age of the Earth.

Sources: en.wikipedia.org

Notes from published material

=== Michael: All American D-Bag === Michael, who calls himself an all-American badass, picked on William because of his culture and hobbies. It is unknown why this episode has never aired in America. However, it has aired on the Fox8 channel of Foxtel and Austar in Australia. It has never been leaked on the internet, and is not available on the Bully Beatdown website. A preview can be seen at the end of Andy's episode. Michael tapped out five times in the first round and was knocked out with a stomach blow in the second. William won $10,000 and an apology from his bully.

Mitochondrial myopathy Maternally inherited diabetes mellitus and deafness (MIDD) While diabetes mellitus and deafness can be found together for other reasons, at an early age this combination can be due to mitochondrial disease, as may occur in Kearns–Sayre syndrome and Pearson syndrome Leber's hereditary optic neuropathy (LHON) LHON is an eye disorder characterized by progressive loss of central vision due to degeneration of the optic nerves and retina (apparently affecting between 1 in 30,000 and 1 in 50,000 people); visual loss typically begins in young adulthood Leigh syndrome, subacute necrotizing encephalomyelopathy after normal development the disease usually begins late in the first year of life, although onset may occur in adulthood a rapid decline in function occurs and is marked by seizures, altered states of consciousness, dementia, ventilatory failure Neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP) progressive symptoms as described in the acronym dementia Myoneurogenic gastrointestinal encephalopathy (MNGIE) gastrointestinal pseudo-obstruction neuropathy MERRF syndrome progressive myoclonic epilepsy "Ragged Red Fibers" are clumps of diseased mitochondria that accumulate in the subsarcolemmal region of the muscle fiber and appear when muscle is stained with modified Gömöri trichrome stain short stature hearing loss lactic acidosis exercise intolerance MELAS syndrome, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes Mitochondrial DNA depletion syndrome Cancer: While the cancer cells prefer Warburg effect however efficient mitochondrial maintenance remains crucial for tumor resilience, redox regulation, and avoidance of cell death. Tumor cells exhibit metabolic heterogeneity, shifting between glycolysis and mitochondrial oxidative phosphorylation to meet energy demands and support growth, especially during metastasis. Key bioenergetic parameters such as oxygen flux, proton leakage, membrane potential, extracellular acidification rate (ECAR), and proton-motive force are examined as “sub-domains” that tumors may regulate to promote survival and evade apoptosis. Conditions such as Friedreich's ataxia can affect the mitochondria but are not associated with mitochondrial proteins.

=== Colonial Police Medal (CPM) === Chan Pak-chi, Superintendent, Royal Hong Kong Police Force. Albert Chan Ting-kai, Senior Divisional Officer, Royal Hong Kong Police Force. Chan Yun-pui, Senior Divisional Officer, Royal Hong Kong Police Force. Cheung Yuk-fung, Superintendent, Royal Hong Kong Police Force. Paul Croft, Senior Superintendent, Royal Hong Kong Police Force. William Frederick Fenton, Senior Superintendent, Royal Hong Kong Police Force. Gillian Suk-han Fletcher, Chief Inspector, Royal Hong Kong Police Force. Fu Keung San-ling, Sergeant, Royal Hong Kong Police Force. Barry Christopher Griffin, Senior Superintendent, Royal Hong Kong Police Force. Tony Ho Tse-tong, Senior Superintendent, Royal Hong Kong Police Force. Victor Hsu Yung, Senior Divisional Officer, Royal Hong Kong Police Force. Kwan Wa-fai, Station Sergeant, Royal Hong Kong Police Force. Lee Yeung-chi, Superintendent, Royal Hong Kong Police Force. Leung Ping, Station Sergeant, Royal Hong Kong Police Force. Li Chun-wai, Station Sergeant, Royal Hong Kong Police Force. Li Kam-wa, Station Sergeant, Royal Hong Kong Police Force. Li Mau-sau, Station Sergeant, Royal Hong Kong Police Force. Liu Tin-chee, Senior Divisional Officer, Royal Hong Kong Police Force. Lo Chan Lin, Station Sergeant, Royal Hong Kong Police Force. Kenneth William Colin Mackenzie, Superintendent, Royal Hong Kong Police Force. Edward Mak Man-poon, Senior Superintendent, Royal Hong Kong Police Force. Martin Samson, Senior Superintendent, Royal Hong Kong Police Force. Tam Sum-wing, Station Sergeant, Royal Hong Kong Police Force.

The bioavailability of spironolactone when taken by mouth is 60 to 90%. The bioavailability of spironolactone and its metabolites increases significantly (+22–95% increases in levels) when spironolactone is taken with food, although it is uncertain whether this further increases the therapeutic effects of the medication. The increase in bioavailability is thought to be due to promotion of the gastric dissolution and absorption of spironolactone, as well as due to a decrease of the first-pass metabolism. The relationship between a single dose of spironolactone and plasma levels of canrenone, a major active metabolite of spironolactone, has been found to be linear across a dose range of 25 to 200 mg spironolactone. Steady-state concentrations of spironolactone are achieved within 8 to 10 days of treatment initiation. Little or no systemic absorption has been observed with topical spironolactone.

== Impact on evolutionary theory == Neutral mutation has become a part of the neutral theory of molecular evolution, proposed in the 1960s. This theory suggests that neutral mutations are responsible for a large portion of DNA sequence changes in a species. For example, bovine and human insulin, while differing in amino acid sequence are still able to perform the same function. The amino acid substitutions between species were seen therefore to be neutral or not impactful to the function of the protein. Neutral mutation and the neutral theory of molecular evolution are not separate from natural selection but add to Darwin's original thoughts. Mutations can give an advantage, create a disadvantage, or make no measurable difference to an organism's survival. A number of observations associated with neutral mutation were predicted in neutral theory including: amino acids with similar biochemical properties should be substituted more often than biochemically different amino acids; synonymous base substitutions should be observed more often than nonsynonymous substitutions; introns should evolve at the same rate as synonymous mutations in coding exons; and pseudogenes should also evolve at a similar rate. These predictions have been confirmed with the introduction of additional genetic data since the theory’s introduction.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network